Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Go back to Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 51.54 +0.19 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.35 | 52 Week High | $17.00 | |||
| Open | $51.39 | 52 Week Low | $3.55 | |||
| Day High | $52.07 | P/E | N/A | |||
| Day Low | $50.88 | EPS | $-1.33 | |||
| Volume | 1,685,309 | |||||
